COVID-19 studies for: C19 studies:  HC QHC Q IvermectinIVM Vitamin DVitamin D ZincZn REGN-COV2REGN LY-CoVLY RemdesivirRMD
HC Q study #158
Source   PDF   Share   Tweet
See all 181 studies
Late treatment study
Choi et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.10.062 (Peer Reviewed)
Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxych loroquine: A nationwide propensity score-matched cohort study
Health insurance database analysis failing to adjust for disease severity and not finding a significant difference in time to PCR- for LPV/r and HC Q.
There are large differences in severity across groups. Authors did PSM but chose not to prioritize severity, resulting in incomparable groups, e.g., baseline pneumonia of 44% in the HC Q group and 15% in the control group (after PSM).
Authors note this but offer no explanation for not correcting for severity: "However, the disease severity and proportion of accompanying pneumonia were still significantly higher in the LPV/r and HC Q-group".
time to viral-, ↑22.0%, p<0.0001, median time to PCR-
Source   PDF   Share   Tweet
See all 181 studies
Please send us corrections, updates, or comments.